After a bleak third quarter, during which venture investments in biotech dropped 12 percent from last year, the sector was due for some good news: Sofinnova Ventures stepped up, closing an oversubscribed $440 million fund to invest in life sciences. (See BioWorld Today, Oct. 5, 2011.)